Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK
Kort samengevat
/PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that its wholly owned...
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij Prnewswire.
Lees het volledige bericht ↗